Jacobio Pharmaceuticals Group Co (HKSE:01167) EV-to-EBIT : -0.55 (As of Dec. 12, 2024)

Jacobio Pharmaceuticals Group Co EV-to-EBIT Chart

Jacobio Pharmaceuticals Group Co Semi-Annual Data
	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
EV-to-EBIT	Get a 7-Day Free Trial							-	-6.70	-	-4.81	-

Competitive Comparison of Jacobio Pharmaceuticals Group Co's EV-to-EBIT

For the Biotechnology subindustry, Jacobio Pharmaceuticals Group Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Jacobio Pharmaceuticals Group Co's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Jacobio Pharmaceuticals Group Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Jacobio Pharmaceuticals Group Co's EV-to-EBIT falls into.

Jacobio Pharmaceuticals Group Co EV-to-EBIT Calculation

Jacobio Pharmaceuticals Group Co's EV-to-EBIT for today is calculated as:

Jacobio Pharmaceuticals Group Co's current Enterprise Value is HK$208.72 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Jacobio Pharmaceuticals Group Co's EBIT for the trailing twelve months (TTM) ended in Jun. 2024 was HK$-382.31 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Jacobio Pharmaceuticals Group Co  (HKSE:01167) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Jacobio Pharmaceuticals Group Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2024 is calculated as:

Jacobio Pharmaceuticals Group Co's Enterprise Value for the quarter that ended in Jun. 2024 was HK$312.24 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Jacobio Pharmaceuticals Group Co's EBIT for the trailing twelve months (TTM) ended in Jun. 2024 was HK$-382.31 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Jacobio Pharmaceuticals Group Co EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Jacobio Pharmaceuticals Group Co's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Jacobio Pharmaceuticals Group Co Business Description